​

Fulcrum Therapeutics (FULC) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

FULC Stock Forecast

Fulcrum Therapeutics (FULC) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $3.60, with a high of $4.00 and a low of $3.00. This represents a 1.41% increase from the last price of $3.55.

$3 $4 $5 $6 $7 $8 $9 $10 $11 High: $4 Avg: $3.6 Low: $3 Last Closed Price: $3.55

FULC Stock Rating

Fulcrum Therapeutics stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (41.18%), 7 Hold (41.18%), 3 Sell (17.65%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 3 7 7 Strong Sell Sell Hold Buy Strong Buy

FULC Price Target Upside V Benchmarks

TypeNameUpside
StockFulcrum Therapeutics1.41%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts5517
Avg Price Target$3.60$3.60$14.12
Last Closing Price$3.55$3.55$3.55
Upside/Downside1.41%1.41%297.75%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26261-110
May, 26261-110
Apr, 26161-19
Mar, 26161-19
Feb, 26261-110
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 02, 2026Andrew FeinH.C. Wainwright$3.00$6.42-53.27%-15.49%
Jun 02, 2026Jefferies$4.00$6.42-37.69%12.68%
Jun 02, 2026Leerink Partners$4.00$6.42-37.69%12.68%
Jun 02, 2026Gregory RenzaTruist Financial$4.00$6.42-37.69%12.68%
Jun 02, 2026Piper Sandler$3.00$6.42-53.27%-15.49%
Feb 24, 2026Gregory RenzaTruist Financial$17.00$8.9689.73%378.87%
Dec 11, 2025Truist Financial$18.00$12.6542.29%407.04%
Dec 08, 2025Stifel Nicolaus$25.00$14.0777.68%604.23%
Dec 08, 2025Kristen KluskaCantor Fitzgerald$24.00$13.7474.67%576.06%
Dec 08, 2025RBC Capital$10.00$14.06-28.88%181.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 02, 2026CitigroupUnderperformUnderweightdowngrade
Jun 02, 2026H.C. WainwrightBuyNeutraldowngrade
Jun 02, 2026Piper SandlerOverweightUnderweightdowngrade
Feb 24, 2026Leerink PartnersOutperformOutperformhold
Feb 24, 2026H.C. WainwrightBuyBuyhold
Dec 08, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 08, 2025RBC CapitalSector PerformSector Performhold
Dec 08, 2025Goldman SachsPositivePositivehold
Dec 08, 2025Bank of America SecuritiesUnderperformUnderperformhold
Dec 08, 2025Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-2.22$-2.35$-1.59$-0.16$-1.18----
Avg Forecast$-2.47$-2.41$-1.64$-0.15$-1.17$-1.19$-1.34$-0.51$0.34
High Forecast$-2.47$-2.41$-1.57$-0.07$-1.12$-0.98$-1.05$-0.51$0.34
Low Forecast$-2.47$-2.41$-1.79$-0.21$-1.20$-1.46$-1.75$-0.51$0.34
Surprise %-10.12%-2.49%-3.05%6.67%0.85%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$19.16M$6.34M$2.81M$80.00M-----
Avg Forecast$14.39M$7.35M$2.31M$80.47M$28.06M$311.89K$361.24M$65.01M$146.15M
High Forecast$14.39M$7.35M$2.90M$80.47M$28.06M$311.89K$361.24M$65.01M$146.15M
Low Forecast$14.39M$7.35M$2.02M$80.47M$28.06M$311.89K$361.24M$65.01M$146.15M
Surprise %33.21%-13.67%21.21%-0.59%-----

Net Income Forecast

$-200M $-150M $-100M $-50M $0 $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-80.85M$-109.87M$-97.33M$-9.72M$-74.88M----
Avg Forecast$-151.14M$-148.00M$-97.33M$-9.72M$-71.72M$-82.27M$-97.66M$-31.61M$20.76M
High Forecast$-151.14M$-148.00M$-96.28M$-4.55M$-69.27M$-61.01M$-65.07M$-31.61M$20.76M
Low Forecast$-151.14M$-148.00M$-109.69M$-13.07M$-74.17M$-90.30M$-108.24M$-31.61M$20.76M
Surprise %-46.51%-25.76%--4.40%----

FULC Forecast FAQ

Is Fulcrum Therapeutics stock a buy?

Fulcrum Therapeutics stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 7 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Fulcrum Therapeutics is a favorable investment for most analysts.

What is Fulcrum Therapeutics's price target?

Fulcrum Therapeutics's price target, set by 17 Wall Street analysts, averages $3.6 over the next 12 months. The price target range spans from $3 at the low end to $4 at the high end, suggesting a potential 1.41% change from the previous closing price of $3.55.

How does Fulcrum Therapeutics stock forecast compare to its benchmarks?

Fulcrum Therapeutics's stock forecast shows a 1.41% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Fulcrum Therapeutics over the past three months?

  • June 2026: 20.00% Strong Buy, 60.00% Buy, 10.00% Hold, 0% Sell, 10.00% Strong Sell.
  • May 2026: 20.00% Strong Buy, 60.00% Buy, 10.00% Hold, 0% Sell, 10.00% Strong Sell.
  • April 2026: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.

What is Fulcrum Therapeutics’s EPS forecast?

Fulcrum Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.19, marking a 0.85% increase from the reported $-1.18 in 2025. Estimates for the following years are $-1.34 in 2027, $-0.51 in 2028, and $0.34 in 2029.

What is Fulcrum Therapeutics’s revenue forecast?

Fulcrum Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $311.89K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $361.24M, followed by $65.01M for 2028, and $146.15M for 2029.

What is Fulcrum Therapeutics’s net income forecast?

Fulcrum Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-82.271M, representing an 9.87% increase from the reported $-74.88M in 2025. Projections indicate $-97.662M in 2027, $-31.612M in 2028, and $20.76M in 2029.